Assetmark Inc. Sells 3,005 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Assetmark Inc. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,975 shares of the biopharmaceutical company’s stock after selling 3,005 shares during the quarter. Assetmark Inc. owned 0.09% of Regeneron Pharmaceuticals worth $71,927,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in REGN. Farther Finance Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 7.9% in the third quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock worth $761,000 after buying an additional 53 shares in the last quarter. Impax Asset Management Group plc increased its holdings in Regeneron Pharmaceuticals by 4.6% during the 3rd quarter. Impax Asset Management Group plc now owns 5,643 shares of the biopharmaceutical company’s stock worth $5,932,000 after acquiring an additional 248 shares during the period. FSM Wealth Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $312,000. Central Bank & Trust Co. lifted its stake in Regeneron Pharmaceuticals by 50.1% in the 3rd quarter. Central Bank & Trust Co. now owns 1,948 shares of the biopharmaceutical company’s stock worth $2,048,000 after purchasing an additional 650 shares in the last quarter. Finally, United Advisor Group LLC boosted its holdings in Regeneron Pharmaceuticals by 68.9% in the 3rd quarter. United Advisor Group LLC now owns 549 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 224 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $675.49 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The firm has a market cap of $73.85 billion, a PE ratio of 17.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The business has a 50 day moving average price of $697.13 and a 200-day moving average price of $859.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.86 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Oppenheimer dropped their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Citigroup decreased their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.